The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Anti-CD34 Antibody Market Research Report 2025
Synopsis
Anti-CD34 Antibody is an antibody that targets CD34, a cell surface protein expressed on hematopoietic stem cells, endothelial progenitor cells, and other cell types. It is commonly used in research to study the role of CD34 in hematopoiesis, angiogenesis, and tumorigenesis. The antibody is also used in clinical applications, such as stem cell transplantation and the diagnosis of certain diseases, including types of cancer and bone marrow disorders.
The global Anti-CD34 Antibody market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The industry trend for Anti-CD34 Antibody has experienced significant growth in recent years, driven by its essential role in stem cell research and its potential applications in regenerative medicine. The antibody's ability to isolate and characterize hematopoietic stem cells has made it a crucial tool for researchers and clinicians. Additionally, the use of Anti-CD34 Antibody in the development of targeted therapies and diagnostic tests for diseases involving CD34 expression, such as leukemia and lymphoma, continues to fuel its demand. As the field of personalized medicine progresses, the utility of Anti-CD34 Antibody in patient diagnosis and treatment is expected to further propel its industry trend.
This report aims to provide a comprehensive presentation of the global market for Anti-CD34 Antibody, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-CD34 Antibody.
Report Scope
The Anti-CD34 Antibody market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-CD34 Antibody market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-CD34 Antibody companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BosterBio
ProSci
GeneTex
Biomatik
MyBioSource
Synaptic Systems
Signalway Antibody
Thermo Fisher Scientific
Biorbyt
NSJ Bioreagents
R&D Systems
Novus Biologicals
LSBio
Abnova Corporation
Bioss
EpiGentek
Wuhan Fine Biotech
BioLegend
StressMarq Biosciences
Segment by Type
Monoclonal Antibody
Polyclonal Antibody
Segment by Application
Biotechnology
Medical
University
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-CD34 Antibody companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Anti-CD34 Antibody is an antibody that targets CD34, a cell surface protein expressed on hematopoietic stem cells, endothelial progenitor cells, and other cell types. It is commonly used in research to study the role of CD34 in hematopoiesis, angiogenesis, and tumorigenesis. The antibody is also used in clinical applications, such as stem cell transplantation and the diagnosis of certain diseases, including types of cancer and bone marrow disorders.
The global Anti-CD34 Antibody market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The industry trend for Anti-CD34 Antibody has experienced significant growth in recent years, driven by its essential role in stem cell research and its potential applications in regenerative medicine. The antibody's ability to isolate and characterize hematopoietic stem cells has made it a crucial tool for researchers and clinicians. Additionally, the use of Anti-CD34 Antibody in the development of targeted therapies and diagnostic tests for diseases involving CD34 expression, such as leukemia and lymphoma, continues to fuel its demand. As the field of personalized medicine progresses, the utility of Anti-CD34 Antibody in patient diagnosis and treatment is expected to further propel its industry trend.
This report aims to provide a comprehensive presentation of the global market for Anti-CD34 Antibody, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-CD34 Antibody.
Report Scope
The Anti-CD34 Antibody market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-CD34 Antibody market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-CD34 Antibody companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BosterBio
ProSci
GeneTex
Biomatik
MyBioSource
Synaptic Systems
Signalway Antibody
Thermo Fisher Scientific
Biorbyt
NSJ Bioreagents
R&D Systems
Novus Biologicals
LSBio
Abnova Corporation
Bioss
EpiGentek
Wuhan Fine Biotech
BioLegend
StressMarq Biosciences
Segment by Type
Monoclonal Antibody
Polyclonal Antibody
Segment by Application
Biotechnology
Medical
University
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-CD34 Antibody companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-CD34 Antibody Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibody
1.2.3 Polyclonal Antibody
1.3 Market by Application
1.3.1 Global Anti-CD34 Antibody Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Biotechnology
1.3.3 Medical
1.3.4 University
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-CD34 Antibody Market Perspective (2019-2030)
2.2 Anti-CD34 Antibody Growth Trends by Region
2.2.1 Global Anti-CD34 Antibody Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Anti-CD34 Antibody Historic Market Size by Region (2019-2024)
2.2.3 Anti-CD34 Antibody Forecasted Market Size by Region (2025-2030)
2.3 Anti-CD34 Antibody Market Dynamics
2.3.1 Anti-CD34 Antibody Industry Trends
2.3.2 Anti-CD34 Antibody Market Drivers
2.3.3 Anti-CD34 Antibody Market Challenges
2.3.4 Anti-CD34 Antibody Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-CD34 Antibody Players by Revenue
3.1.1 Global Top Anti-CD34 Antibody Players by Revenue (2019-2024)
3.1.2 Global Anti-CD34 Antibody Revenue Market Share by Players (2019-2024)
3.2 Global Anti-CD34 Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Anti-CD34 Antibody Revenue
3.4 Global Anti-CD34 Antibody Market Concentration Ratio
3.4.1 Global Anti-CD34 Antibody Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-CD34 Antibody Revenue in 2023
3.5 Anti-CD34 Antibody Key Players Head office and Area Served
3.6 Key Players Anti-CD34 Antibody Product Solution and Service
3.7 Date of Enter into Anti-CD34 Antibody Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-CD34 Antibody Breakdown Data by Type
4.1 Global Anti-CD34 Antibody Historic Market Size by Type (2019-2024)
4.2 Global Anti-CD34 Antibody Forecasted Market Size by Type (2025-2030)
5 Anti-CD34 Antibody Breakdown Data by Application
5.1 Global Anti-CD34 Antibody Historic Market Size by Application (2019-2024)
5.2 Global Anti-CD34 Antibody Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Anti-CD34 Antibody Market Size (2019-2030)
6.2 North America Anti-CD34 Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Anti-CD34 Antibody Market Size by Country (2019-2024)
6.4 North America Anti-CD34 Antibody Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-CD34 Antibody Market Size (2019-2030)
7.2 Europe Anti-CD34 Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Anti-CD34 Antibody Market Size by Country (2019-2024)
7.4 Europe Anti-CD34 Antibody Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-CD34 Antibody Market Size (2019-2030)
8.2 Asia-Pacific Anti-CD34 Antibody Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Anti-CD34 Antibody Market Size by Region (2019-2024)
8.4 Asia-Pacific Anti-CD34 Antibody Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Anti-CD34 Antibody Market Size (2019-2030)
9.2 Latin America Anti-CD34 Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Anti-CD34 Antibody Market Size by Country (2019-2024)
9.4 Latin America Anti-CD34 Antibody Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-CD34 Antibody Market Size (2019-2030)
10.2 Middle East & Africa Anti-CD34 Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Anti-CD34 Antibody Market Size by Country (2019-2024)
10.4 Middle East & Africa Anti-CD34 Antibody Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BosterBio
11.1.1 BosterBio Company Detail
11.1.2 BosterBio Business Overview
11.1.3 BosterBio Anti-CD34 Antibody Introduction
11.1.4 BosterBio Revenue in Anti-CD34 Antibody Business (2019-2024)
11.1.5 BosterBio Recent Development
11.2 ProSci
11.2.1 ProSci Company Detail
11.2.2 ProSci Business Overview
11.2.3 ProSci Anti-CD34 Antibody Introduction
11.2.4 ProSci Revenue in Anti-CD34 Antibody Business (2019-2024)
11.2.5 ProSci Recent Development
11.3 GeneTex
11.3.1 GeneTex Company Detail
11.3.2 GeneTex Business Overview
11.3.3 GeneTex Anti-CD34 Antibody Introduction
11.3.4 GeneTex Revenue in Anti-CD34 Antibody Business (2019-2024)
11.3.5 GeneTex Recent Development
11.4 Biomatik
11.4.1 Biomatik Company Detail
11.4.2 Biomatik Business Overview
11.4.3 Biomatik Anti-CD34 Antibody Introduction
11.4.4 Biomatik Revenue in Anti-CD34 Antibody Business (2019-2024)
11.4.5 Biomatik Recent Development
11.5 MyBioSource
11.5.1 MyBioSource Company Detail
11.5.2 MyBioSource Business Overview
11.5.3 MyBioSource Anti-CD34 Antibody Introduction
11.5.4 MyBioSource Revenue in Anti-CD34 Antibody Business (2019-2024)
11.5.5 MyBioSource Recent Development
11.6 Synaptic Systems
11.6.1 Synaptic Systems Company Detail
11.6.2 Synaptic Systems Business Overview
11.6.3 Synaptic Systems Anti-CD34 Antibody Introduction
11.6.4 Synaptic Systems Revenue in Anti-CD34 Antibody Business (2019-2024)
11.6.5 Synaptic Systems Recent Development
11.7 Signalway Antibody
11.7.1 Signalway Antibody Company Detail
11.7.2 Signalway Antibody Business Overview
11.7.3 Signalway Antibody Anti-CD34 Antibody Introduction
11.7.4 Signalway Antibody Revenue in Anti-CD34 Antibody Business (2019-2024)
11.7.5 Signalway Antibody Recent Development
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Detail
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Anti-CD34 Antibody Introduction
11.8.4 Thermo Fisher Scientific Revenue in Anti-CD34 Antibody Business (2019-2024)
11.8.5 Thermo Fisher Scientific Recent Development
11.9 Biorbyt
11.9.1 Biorbyt Company Detail
11.9.2 Biorbyt Business Overview
11.9.3 Biorbyt Anti-CD34 Antibody Introduction
11.9.4 Biorbyt Revenue in Anti-CD34 Antibody Business (2019-2024)
11.9.5 Biorbyt Recent Development
11.10 NSJ Bioreagents
11.10.1 NSJ Bioreagents Company Detail
11.10.2 NSJ Bioreagents Business Overview
11.10.3 NSJ Bioreagents Anti-CD34 Antibody Introduction
11.10.4 NSJ Bioreagents Revenue in Anti-CD34 Antibody Business (2019-2024)
11.10.5 NSJ Bioreagents Recent Development
11.11 R&D Systems
11.11.1 R&D Systems Company Detail
11.11.2 R&D Systems Business Overview
11.11.3 R&D Systems Anti-CD34 Antibody Introduction
11.11.4 R&D Systems Revenue in Anti-CD34 Antibody Business (2019-2024)
11.11.5 R&D Systems Recent Development
11.12 Novus Biologicals
11.12.1 Novus Biologicals Company Detail
11.12.2 Novus Biologicals Business Overview
11.12.3 Novus Biologicals Anti-CD34 Antibody Introduction
11.12.4 Novus Biologicals Revenue in Anti-CD34 Antibody Business (2019-2024)
11.12.5 Novus Biologicals Recent Development
11.13 LSBio
11.13.1 LSBio Company Detail
11.13.2 LSBio Business Overview
11.13.3 LSBio Anti-CD34 Antibody Introduction
11.13.4 LSBio Revenue in Anti-CD34 Antibody Business (2019-2024)
11.13.5 LSBio Recent Development
11.14 Abnova Corporation
11.14.1 Abnova Corporation Company Detail
11.14.2 Abnova Corporation Business Overview
11.14.3 Abnova Corporation Anti-CD34 Antibody Introduction
11.14.4 Abnova Corporation Revenue in Anti-CD34 Antibody Business (2019-2024)
11.14.5 Abnova Corporation Recent Development
11.15 Bioss
11.15.1 Bioss Company Detail
11.15.2 Bioss Business Overview
11.15.3 Bioss Anti-CD34 Antibody Introduction
11.15.4 Bioss Revenue in Anti-CD34 Antibody Business (2019-2024)
11.15.5 Bioss Recent Development
11.16 EpiGentek
11.16.1 EpiGentek Company Detail
11.16.2 EpiGentek Business Overview
11.16.3 EpiGentek Anti-CD34 Antibody Introduction
11.16.4 EpiGentek Revenue in Anti-CD34 Antibody Business (2019-2024)
11.16.5 EpiGentek Recent Development
11.17 Wuhan Fine Biotech
11.17.1 Wuhan Fine Biotech Company Detail
11.17.2 Wuhan Fine Biotech Business Overview
11.17.3 Wuhan Fine Biotech Anti-CD34 Antibody Introduction
11.17.4 Wuhan Fine Biotech Revenue in Anti-CD34 Antibody Business (2019-2024)
11.17.5 Wuhan Fine Biotech Recent Development
11.18 BioLegend
11.18.1 BioLegend Company Detail
11.18.2 BioLegend Business Overview
11.18.3 BioLegend Anti-CD34 Antibody Introduction
11.18.4 BioLegend Revenue in Anti-CD34 Antibody Business (2019-2024)
11.18.5 BioLegend Recent Development
11.19 StressMarq Biosciences
11.19.1 StressMarq Biosciences Company Detail
11.19.2 StressMarq Biosciences Business Overview
11.19.3 StressMarq Biosciences Anti-CD34 Antibody Introduction
11.19.4 StressMarq Biosciences Revenue in Anti-CD34 Antibody Business (2019-2024)
11.19.5 StressMarq Biosciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
